Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Economic Development topic
No spam. Unsubscribe anytime.
Council approves up to $600,000 in performance incentive for ARL Biopharma expansion, pledges 400 jobs
Summary
Council approved a joint resolution with the Oklahoma City Economic Development Trust to allocate up to $600,000 in general obligation limited tax bond proceeds to support ARL Biopharma’s planned facility expansion, which company representatives said will add roughly 400 jobs and $46.75 million in capital investment.
The Oklahoma City Council approved a resolution authorizing up to $600,000 in performance‑based incentives from general obligation limited tax bond proceeds for ARL Biopharma’s planned expansion in Oklahoma City.
City economic development staff and Alliance representatives described the incentive as a pay‑for‑performance allocation tied to job creation. Alliance staff said the company anticipates creating about 400 new, market‑quality jobs over a multi‑year period (the company described a five‑year expectation but the city item authorized up to seven years for performance benchmarks) with average wages starting near $68,000 and rising in later years; ARL executives described additional capital investment of approximately $46.75 million.
Vince Bob, COO of ARL Biopharma, described the company’s growth, its existing footprint in the OU Research Park and plans to expand bioanalytical testing capabilities to support biologics and manufacturing partners. The council approved the allocation and authorized staff to negotiate an economic development agreement (a final trust agreement and subsequent council concurrence were described as next steps).
The incentive is structured as a pay‑for‑performance grant tied to job and investment milestones; city staff and the Alliance will finalize the agreement that spells out performance conditions, clawback provisions and the schedule for payments. Council members welcomed the expansion and emphasized the company’s role in retaining and growing a biopharma presence in the city.
City staff will return with the executed economic development agreement for trust and council concurrence and provide reporting on job and investment milestones as the project proceeds.
